Island Pharmaceuticals Limited (ILA.AX)
- Previous Close
0.0530 - Open
0.0500 - Bid 0.0500 x --
- Ask 0.0560 x --
- Day's Range
0.0500 - 0.0530 - 52 Week Range
0.0500 - 0.1450 - Volume
67,930 - Avg. Volume
202,192 - Market Cap (intraday)
6.031M - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was incorporated in 2020 and is based in Camberwell, Australia.
www.islandpharmaceuticals.comRecent News: ILA.AX
Performance Overview: ILA.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ILA.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ILA.AX
Valuation Measures
Market Cap
6.03M
Enterprise Value
5.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.46
Enterprise Value/Revenue
502.76
Enterprise Value/EBITDA
-2.36
Financial Highlights
Profitability and Income Statement
Profit Margin
-247.34%
Return on Assets (ttm)
-56.82%
Return on Equity (ttm)
-134.02%
Revenue (ttm)
960.12k
Net Income Avi to Common (ttm)
-2.37M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
976.05k
Total Debt/Equity (mrq)
79.63%
Levered Free Cash Flow (ttm)
-2.02M
Company Insights: ILA.AX
ILA.AX does not have Company Insights